|
|
| Enbrel |
All Financial Data in US $ (mln) |
|
Word Search (Top 10 - by date)
|
Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37
Amgen
(July 29, 2014)
|
PFIZER REPORTS SECOND-QUARTER 2014 RESULTS
Pfizer
(July 29, 2014)
|
Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)
Coherus BioSciences
(July 16, 2014)
|
| Global Biological Drugs Market is Expected to Reach USD 287,139.7 Million in 2020: Transparency Market Research
(July 16, 2014)
|
CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment
CEL-SCI
(July 15, 2014)
|
Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease
Protalix BioTherapeutics
(June 18, 2014)
|
AVERT Trial Demonstrates High Rates of DAS-defined Remission with Orencia® (abatacept) in Combination with Methotrexate (MTX) in Adult Patients with Early Rheumatoid Arthritis (RA)
Bristol-Myers Squibb
(June 10, 2014)
|
Ironwood Pharmaceuticals Appoints Douglas Williams, Ph.D., to Board of Directors
Ironwood Pharmaceuticals
(June 04, 2014)
|
Oncos Therapeutics Recruits Dr Magnus Jaderberg as CMO to Strengthen its Focus on Cancer Immunotherapy
Oncos Therapeutics
(June 04, 2014)
|
Pfizer Announces Detailed Results For Phase 3 OPT Retreatment Study Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis
Pfizer
(May 23, 2014)
|
|
|
|
|
EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.
|
|
Product Sales Summary 2010/11
|
|
Annual Sales WW - Sales
|
Growth per Year (%)
|
|
Rank1 |
Generic Name
|
Therapeutic Subcategory
|
2010 |
2011 |
2011 |
| Enbrel2 |
|
|
|
7,257 |
7,892 |
|
+9% |
|
|
Note: Shaded Cells3 |
|
|
|
Clinical Trial Coverage: No. of Trials involving Product
|
|
|
|
Welcome
Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.
Explore Evaluate
Partnering
EvaluatePharma® now includes Partnering Opportunities - products available for licensing.
Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.
Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.
Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.
Register to access more FREE content:
- 2011 Product Sales analysis
- Download analysis into Excel
- Search 2 yrs of company press releases
Register for Free Analysis
Register to access more free insights and analysis from Evaluate.
Register Now
|
|
|
|